| P2093 | author name string | Michelle D Liedtke | |
| | R Chris Rathbun | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin | Q28376604 |
| | The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q31114479 |
| | Need for increased dose of warfarin in HIV patients taking nevirapine | Q32054863 |
| | Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors | Q32064655 |
| | Molecular basis of ethnic differences in drug disposition and response | Q34192804 |
| | Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir | Q34633457 |
| | Potential interaction involving warfarin and ritonavir | Q34756237 |
| | Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir | Q36094057 |
| | The pharmacogenetics of coumarin therapy. | Q36192806 |
| | Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors | Q36544977 |
| | Interaction between lopinavir/ritonavir and warfarin | Q36910151 |
| | Venous thromboembolism in patients with HIV/AIDS: a case-control study | Q37003352 |
| | Inhibition and induction of human cytochrome P450 enzymes: current status | Q37212794 |
| | Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery | Q37367170 |
| | Human P450 metabolism of warfarin | Q41334623 |
| | Possible antiretroviral therapy-warfarin drug interaction | Q43977905 |
| | Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations | Q44486357 |
| | Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions | Q44735365 |
| | CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy | Q44787221 |
| | Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series | Q45108757 |
| | Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions | Q45401784 |
| | Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans | Q46174502 |
| | Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment | Q46826197 |
| | Several-fold increase in risk of overanticoagulation by CYP2C9 mutations | Q46830669 |
| | Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. | Q46975102 |
| | Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. | Q52550127 |
| | Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 |
| | Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. | Q53608173 |
| | Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man | Q54693988 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 215-223 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Drug interactions with antiretrovirals and warfarin | |
| P478 | volume | 9 | |